Opioids,cannabis, confidentiality,ethics, buprenorphine among highlights of 2019

Opioids are still the dominant news story in the substance use disorder (SUD) field. Last year saw continued funding from the Substance Abuse and Mental Health Services Administration — and, of course, Congress — for the treatment field. Formulations of buprenorphine, the looming loss of confidentiality protections, the growing acceptance of cannabis, and a focus on quality and ethics were among the important stories for ADAW readers.